Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1

Interventions

Specimen Handling 276pembrolizumab 227Magnetic Resonance Spectroscopy 226Carboplatin 180Cisplatin 166Biopsy 166Nivolumab 158Cyclophosphamide 144Radiotherapy 125Paclitaxel 124Gemcitabine 116Bevacizumab 95durvalumab 92Dexamethasone 88Rituximab 81Oxaliplatin 80venetoclax 75atezolizumab 71Fluorouracil 70Docetaxel 70Capecitabine 70Doxorubicin 68Etoposide 65Radiosurgery 64Ipilimumab 63Radiation 61Prednisone 60Cytarabine 60Lenalidomide 58Pemetrexed 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ophthalmic Solutions × 90 days × Clear all
NCT06365853 2026-03-25

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

AbbVie

Phase 2 Recruiting
100 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡